Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases

被引:187
作者
McKay, JA
Murray, LJ
Curran, S
Ross, VG
Clark, C
Murray, GI
Cassidy, J
McLeod, HL
机构
[1] Univ Aberdeen, Dept Med & Therapeut, Aberdeen AB25 2ZD, Scotland
[2] Univ Aberdeen, Dept Pathol, Aberdeen AB25 2ZD, Scotland
关键词
colorectal cancer; epidermal growth factor receptor; prognosis; polymorphism; immunohistochemistry; lymph node metastases;
D O I
10.1016/S0959-8049(02)00234-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Overexpression of the epidermal growth factor receptor (EGFR) often correlates with an aggressive tumour phenotype and poor prognosis. To examine the relevance of EGFR in colorectal cancer, we determined the expression of EGFR protein in 249 colorectal adenocarcinomas and 42 lymph node metastases using immunohistochemistry. Moreover, we investigated a (CA)(n) dinucleotide repeat polymorphism of the EGFR gene in a subset of 114 tumours. High levels of EGFR protein were observed in 123/249 (49.4%) samples. EGFR expression in colorectal carcinomas correlated with differentiation grade (P = 0.014). However, there were no associations with Dukes' stage, site, patient age or gender. EGFR protein expression did not influence survival in this colorectal cancer patient cohort (P greater than or equal to 0.05). Expression was not identical in paired colorectal tumours and lymph node metastases, with only 17/42 (40.5%) samples showing equivalent EGFR levels (P > 0.05). The distribution of the (CA)(n) dinucleotide repeat alleles in colorectal adenocarcinomas was not associated with EGFR protein expression (P > 0.05). These results indicate that while EGFR overexpression is a common event in colorectal carcinogenesis, it does not influence patient prognosis. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:2258 / 2264
页数:7
相关论文
共 28 条
[21]   EPIDERMAL GROWTH-FACTOR RECEPTOR (EGFR) - RESULTS OF A 6 YEAR FOLLOW-UP-STUDY IN OPERABLE BREAST-CANCER WITH EMPHASIS ON THE NODE NEGATIVE SUBGROUP [J].
NICHOLSON, S ;
RICHARD, J ;
SAINSBURY, C ;
HALCROW, P ;
KELLY, P ;
ANGUS, B ;
WRIGHT, C ;
HENRY, J ;
FARNDON, JR ;
HARRIS, AL .
BRITISH JOURNAL OF CANCER, 1991, 63 (01) :146-150
[22]   ESTIMATES OF THE WORLDWIDE INCIDENCE OF 18 MAJOR CANCERS IN 1985 [J].
PARKIN, DM ;
PISANI, P ;
FERLAY, J .
INTERNATIONAL JOURNAL OF CANCER, 1993, 54 (04) :594-606
[23]  
RADINSKY R, 1995, CLIN CANCER RES, V1, P19
[24]   Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer [J].
Reissmann, PT ;
Koga, H ;
Figlin, RA ;
Holmes, EC ;
Salmon, DJ .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1999, 125 (02) :61-70
[25]   A comparative study of nucleolar organizer region, proliferating cell nuclear antigen and epidermal growth factor receptor staining in colon tumours [J].
Shimada, N ;
Suzuki, J ;
Fujita, J ;
Kawakami, Y ;
Tsukakoshi, H ;
Hosokawa, M ;
Sato, N .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1998, 13 (08) :794-800
[26]  
TATEISHI M, 1990, CANCER RES, V50, P7077
[27]   When is a tumor marker ready for prime time?: A case study of c-erbB-2 as a predictive factor in breast cancer [J].
Yamauchi, H ;
Stearns, V ;
Hayes, DF .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2334-2356
[28]   The EGF receptor as central transducer of heterologous signalling systems [J].
Zwick, E ;
Hackel, PO ;
Prenzel, N ;
Ullrich, A .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1999, 20 (10) :408-412